Clinical Trials Browser

INDUSTRY × Interventional × naquotinib × Clear all

NCT02588261 2024-12-10

SOLAR

Phase 3 Terminated

530 enrolled 25 charts

Carcinoma, Non-Small-Cell Lung

NCT02500927 2024-11-20

A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations

Phase 2 Terminated

Carcinoma, Non-Small-Cell Lung

NCT03082300 2024-11-20

A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT02113813 2024-11-14

A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT02192697 2024-11-14

An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

Phase 1/2 Terminated

Carcinoma, Non-Small-Cell Lung

NCT02674555 2017-07-28

A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors

Phase 1 Withdrawn

Neoplasms

NCT03042013 2017-07-11

A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung, Neoplasms